Agenus Inc. (AGEN)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 5.0000 |
| Open | 4.9900 |
| Bid | 4.9200 x 200 |
| Ask | 4.9700 x 200 |
| Day's range | 4.8299 - 5.1000 |
| 52-week range | 4.4100 - 27.2000 |
| Volume | |
| Avg. volume | 746,670 |
| Market cap | 106.781M |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.1400 |
| Earnings date | 05 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.75 |
- Business Wire
Agenus to Participate in September Investor Conferences
LEXINGTON, Mass., September 03, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Agenus executives, Dr. Garo Armen, Chief Executive Officer, Robin Taylor, Chief Commercial Officer, and Zack Armen, Head of Investor Relations, will participate in the following upcoming investor conferences:
ZacksAgenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -89.47% and 63.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press Finance
Agenus: Q2 Earnings Snapshot
LEXINGTON, Mass. AP) — Agenus Inc. AGEN) on Thursday reported a loss of $54.8 million in its second quarter.
© 2024 Yahoo. All rights reserved.